1. Home
  2. BRR vs SPRO Comparison

BRR vs SPRO Comparison

Compare BRR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRR

Columbus Circle Capital Corp I Class A Ordinary Shares

HOLD

Current Price

$1.69

Market Cap

174.8M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.19

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRR
SPRO
Founded
2024
2013
Country
United States
United States
Employees
5
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.8M
156.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
BRR
SPRO
Price
$1.69
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
861.1K
2.1M
Earning Date
06-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$1.31
$1.08
52 Week High
$10.51
$3.08

Technical Indicators

Market Signals
Indicator
BRR
SPRO
Relative Strength Index (RSI) 44.10 21.32
Support Level $1.41 $1.08
Resistance Level $2.13 $2.42
Average True Range (ATR) 0.16 0.15
MACD -0.03 -0.01
Stochastic Oscillator 2.83 7.14

Price Performance

Historical Comparison
BRR
SPRO

About BRR Columbus Circle Capital Corp I Class A Ordinary Shares

ProCap Financial Inc is focused on Bitcoin-focused media products and Bitcoin holdings. The Company typically provides advertising and marketing services through weekly digital media placements, including audio and social media advertisements. The Company offers media products to help independent investors understand financial markets, current events, and technology advancements. These media products include social media accounts, email newsletters, and audio or video content. The Company also added strategies related to the use of AI and automation to support the development and delivery of financial products and services.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: